Alkermes
artistry melanoma cohort focused on unmet need key inclusion criteria artistry study melanoma cohort progressed on immune inhibitor anti with or without anti targeted agent as appropriate inhibitor if protocol defined efficacy response criteria achieved triggered two stage expansion cohort second stage of enrollment underway artistry two stage stage enroll more if stage refractory melanoma expansion total | Alkermes
Company
Deck Type
Sector
Industry
Deck date
March 2021
Slide
66 of 144
Similar slides by Alkermes
See diffirences between slides (animation)
Results
June 2021
artistry cohort enrollment completed | Alkermes
Related slides by other companies
Immatics
Investor Presentation
November 2023
interim update | Immatics
Immatics
Investor Presentation
November 2023
interim update | Immatics
Kore
Results
May 2023
global sales pipeline as of march qualification technical evaluation stage proposal stage contract signed stage beta site stage closed won kore | Kore
Immatics
Investor Presentation
November 2023
interim update | Immatics
Other recent decks by Alkermes
See all presentations (22 decks)
Investor Conference
January 2024
Results
October 2023
Investor Presentation
October 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io